Specifically, decreased anxiety-like behavior [23,24], decreased depression-like behavior [25,26], decreased ethanol consumption [27,28], and decreased susceptibility to pilocarpine- and picrotoxin-induced seizures [29] have all been seen following GLO1 inhibitor treatment. This evidence concerns the gene GLO1 and depressive symptom measurement.